Cambron-Mellott, M. Janelle
Mettam, Sam http://orcid.org/0000-0003-3656-4089
Li, Vicky W.
Rowland, John C.
Castro, JeanPierre Coaquira
Funding for this research was provided by:
Jazz Pharmaceuticals
Article History
Received: 7 February 2022
Accepted: 5 August 2022
First Online: 25 August 2022
Declarations
:
: The protocol and questionnaire for the 2016 and 2017 NHWS were reviewed and granted exemption by the Pearl Institutional Review Board (IRB) as it was determined this study met the exemption requirements under 45CFR46.101(b)(2). Informed consent was obtained from all respondents electronically.
: Not applicable.
: MJCM and VL are employees of Cerner Enviza, which received funding from Jazz Pharmaceuticals for study conduct and manuscript preparation. At the time of study conduct, JCR was an employee of Kantar Health, now Cerner Enviza, which received funding from Jazz Pharmaceuticals for study conduct and manuscript preparation. SM is an employee of Jazz Pharmaceuticals who, in the course of their employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. At the time of study conduct, JPCC was an employee of Jazz Pharmaceuticals who, in the course of their employment, received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc.